Simplify your Transfection Workflow

ZymoPURE II Plasmid Purification Kits

Image of manifold buffers Image of manifold buffers Image of manifold buffers

Ultra-Fast Midi & Maxipreps

Watch the Video

PROTOCOL
DATA SHEET
GET FREE SAMPLE
Image of a stopwatch.

Fastest

Simple 16-minute Midi/Maxi preps

Image of four bars placed in order of ascending height, with the last bar being an arrow pointing upwards.

Highest Yield

Up to 3 mg from a spin-column

Image a water drop.

Ultra-Pure

Endotoxin-Free & Transfection Ready

Plasmid Purification Reinvented

Save more than 2 hours per prep!
Plasmid Purification
Image of a automation processing machine.
Image of a automation processing machine.
Image of a horizontal bar graph showing the protocol length, in minutes, with ZymoPURE II only taking 16 minutes.
Simply bind, wash, and elute.

Simply bind, wash and elute. Novel binding chemistry and spin-column enables simple purification of transfection-ready plasmid DNA up to 9x faster using a vacuum manifold or centrifuge. No slow gravity flow columns, no tedious alcohol precipitation.

Highest Yield. Lowest Elution Volume.

Up to 6x More Concentrated Plasmid
Up to 3x More Plasmid DNA Yield

Yield and concentration for plasmid DNA isolated using the ZymoPURE II Maxiprep kit compared to two endotoxin-free kits from Supplier Q and Supplier MN. Plasmid DNA (pGL3®) was isolated from 150 ml of JM109 E. coli culture grown overnight following the manufacturer’s suggested protocol (in duplicate). One (1) µl of eluted plasmid DNA was visualized post agarose gel electrophoresis. M, ZR 1 kb DNA Marker (Zymo Research).

Transfection-Grade Plasmid DNA

Transfection-grade Plasmid DNA
Transfection-grade Plasmid DNA 400x less endotoxin

Endotoxin-Free

Achieve 4x less endotoxin
compared to the industry standard

Transfection-grade Plasmid DNA application ready

Application-ready

CRISPR, gene modification, lentiviral vectors, synthetic biology, etc.

Transfection-grade Plasmid DNA ultra-pure

Ultra-Pure

For sensitive primary cells,
in vivo injections, cloning, etc.

Superior Transfection Efficiency

HeLa Cells seeded in a 6-well plate were transfected with either 2 or 4 µg of pCI-neo®+GFP plasmid isolated from 100 ml of bacteria culture using the ZymoPURE Midiprep Kit, ZymoPURE Maxiprep Kit, or MN Midiprep Kit. GFP expressin was assessed 48 hours later in cell lysates using western blot and Ponceau S staining. The blot was also probed with an antibody against alpha-Tubulin in order to verify equal loading samples.

Data generated by V.B. at University of Cologne

Plasmid Purity Redefined

Transfection-grade Plasmid DNA

The EndoZero column eliminates residual endotoxins, yielding plasmid DNA with endotoxin levels below FDA limits for vaccines*. This means plasmid is suitable for sensitive applications like transfection of primary cells, in vivo injections, gene editing and recombinant viral vector production.

* Defined as endotoxins below the FDA limit for vaccines (< 0.04 EU/µg of plasmid DNA)

Colored Buffers Enable Easy, Error-free Preparation

Visualize alkaline lysis and neutralization steps using a patented multi-colored buffer system that enables easy determination of complete cell lysis and neutralization to prevent errors in processing.

Advanced EZ-Flow Spin-Column Technology

Our patented ZymoPURE plasmid purification system features a novel binding chemistry and EZ-Flow™ Spin-Column design that enables high DNA binding capacity and rapid loading of the lysate and wash buffer via vacuum or centrifuge resulting in the purification of highly concentrated (up to 6 mg/ml) endotoxin-free plasmid DNA directly from a spin-column in only 16 minutes.

Unrivaled Technology

ZymoPURE II Maxiprep Kit Supplier Q Endofree Maxiprep Supplier MN Endofree Maxiprep
Maximum Yield 3,000 µg 500 µg* 2,000 µg*
Format Spin-Column Anion-Exchange Anion-Exchange
Prep Time 16 Minutes 150 Minutes 90 Minutes
6 Minute Bind, Wash, Elute
Spin Column Elution
Alcohol Precipitation-Free
Endotoxin-Free**

*Manufacturer's stated maximum yield

**Defined as < 0.1 EU/µg of plasmid DNA

ZymoPURE plasmid purification kits are the fastest and simplest plasmid purification methods available to efficiently isolate a high yield of transfection-grade plasmid DNA from E. coli in as little as 16 minutes. Plasmid DNA is endotoxin-free and ready for immediate use in downstream applications such as transfection, in vivo injections, in vitro transcription, molecular cloning, PCR, and many more.

Cited for Sensitive Applications

Cell Therapy   |   Gene Therapy   |   Protein Replacement Therapy   |  
Recombinant Antibody Therapy   |  
Vaccine Development   |  
CAR T-Cell Therapy/Immunotherapy   |   Transfection   |  
Gene Editing   |  
Viral Vector Production (Lentivirus/Adenovirus/AAV)  |  
In vitro transcription/translation   |  
Transgenic organism generation   |   Microinjection of embryos   |  
and more…

SelectScience® Gold Seal of Quality

SelectScience® Gold Seal of Quality SelectScience® Seals of Quality recognize products that have consistently received multiple positive reviews on SelectScience® and are designed to assist scientists in making important purchasing decisions.

Image of SafeCollect samples being processed by a machine

What People Are Saying

Top Companies & Institutions Rely On ZymoPURE Plasmid Purification

ZymoPURE Plasmid Purification Kits

ZymoPURE Plasmid Miniprep Kit ZymoPURE II Plasmid Midiprep Kit ZymoPURE II Plasmid Maxiprep Kit ZymoPURE II Plasmid Gigaprep Kit
Processing Volume ≤ 5 ml ≤ 50 ml ≤ 150 ml ≤ 2.5 L
Processing Time ≤ 15 minutes ≤ 18 minutes ≤ 18 minutes ≤ 45 minutes
Yield ≤ 100 µg ≤ 1.2 mg ≤ 3.0 mg ≤ 25 mg
Elution Volume ≥ 25 µl ≥ 150 µl ≥ 300 µl ≥ 3 ml
Endotoxins ≤ 1 EU/µg DNA ≤ 0.025 EU/µg DNA ≤ 0.025 EU/µg DNA ≤ 0.025 EU/µg DNA
Instruction Manual
Sample Get Free Sample Get Free Sample Get Free Sample

The ZymoPURE family of plasmid purification kit formats handle different amounts of culture input, ranging from miniprep (≤ 5 ml), midiprep (≤ 50 ml), maxiprep (≤ 150 ml) and gigaprep (≤ 2.5 L).

ZymoPURE Plasmid Purification Kits Product Description

The ZymoPURE plasmid purification kits are the best method for rapid isolation of transfection ready plasmid DNA. Plasmid purification for Minipreps, Midipreps and Maxipreps is performed in less than 18 minutes and Gigapreps in 45 minutes. This family of plasmid purification kits feature a patented binding chemistry that enables simple purification of highly concentrated (up to 6 mg/ml) endotoxin-free plasmid DNA using a spin-column. The streamlined workflow eliminates slow gravity flow anion-exchange columns and isopropanol precipitation steps found in other kits. ZymoPURE plasmid purification kits reduce processing time by up to 9x using a vacuum manifold or centrifuge. Simply bind, wash, and elute transfection ready, endotoxin-free plasmid in minutes.

The ZymoPURE plasmid purification kits are optimized to ensure the eluted DNA is free of endotoxins, salt, protein, and RNA, resulting in plasmids that are suitable for use in sensitive applications. ZymoPURE II plasmid purification kits include the EndoZero columns that enable rapid isolation of endotoxin-free plasmid DNA. The resulting endotoxin-free plasmid DNA is ideal for transfection (including sensitive and primary cells), CRISPR-Cas9 and gene editing, lentiviral vectors, adenovirus vectors, AAV vectors, gene therapy, chimeric antigen receptor (CAR) generation, recombinant antibody generation, in vitro transcription, synthetic biology, PCR8, transgenic organism generation and microinjections, molecular cloning, restriction endonuclease digestions, site-directed mutagenesis, plasmid transformation of competent cells, Sanger sequencing, and other sensitive downstream applications.

Buy Now

ZymoPURE Citations for Sensitive Applications

  1. Ramos-Murillo, Ana Isabel, et al. Efficient Non-Viral Gene Modification of Mesenchymal Stromal Cells from Umbilical Cord Wharton’s Jelly with Polyethylenimine. Pharmaceutics 12 9 896 2020.
  2. Vaughan, Hannah J, et al. Poly (beta-amino ester) nanoparticles enable tumor-specific TRAIL secretion and a bystander effect to treat liver cancer. Molecular Therapy-Oncolytics 21 377-388 2021.
  3. Lemmerman, Luke R, et al. Nanotransfection-based vasculogenic cell reprogramming drives functional recovery in a mouse model of ischemic stroke. Science Advances 712 eabd4735 2021.
  4. Gross, Tobias, et al. Characterization of CRISPR/Cas9 RANKL knockout mesenchymal stem cell clones based on single-cell printing technology and Emulsion Coupling assay as a low-cellularity workflow for single-cell cloning. Plos one 16 3 e0238330 2021.
  5. Tang, Shirley, et al. Nonviral Transfection With Brachyury Reprograms Human Intervertebral Disc Cells to a Pro‐Anabolic Anti‐Catabolic/ Inflammatory Phenotype: A Proof of Concept Study. Journal of Orthopaedic Research 37 11 2389-2400 2019.
  6. McMahon, Moira A, et al. Gene disruption using chemically modified CRISPR-Cpf1 RNA. CRISPR Guide RNA Design 49-60 2021.
  7. Zhang, Liyang, et al. AsCas12a ultra nuclease facilitates the rapid generation of therapeutic cell medicines. Nature Communications 12 1 44211 2021.
  8. Moore, Jordan T, et al. Nanochannel‐Based Poration Drives Benign and Effective Nonviral Gene Delivery to Peripheral Nerve Tissue. Advanced Biosystems 4 11 2000157 2020.
  9. Tang, S, et al. Non-viral reprogramming of human nucleus pulposus cells with FOXF1 via extracellular vesicle delivery: an in vitro and in vivo study. European Cells & Materials 41 90-107 2021.
  10. Chamberlain, Kyle, et al. A calsequestrin cis-regulatory motif coupled to a cardiac troponin T promoter improves cardiac adeno-associated virus serotype 9 transduction specificity. Human Gene Therapy 29 8 927-937 2018.
  11. Roy, Sashwati, et al. Neurogenic tissue nanotransfection in the management of cutaneous diabetic polyneuropathy. Nanomedicine: Nanotechnology, Biology and Medicine 2 102220 2020.
  12. Alzate-Correa, Diego, et al. Isolation and Nanoscale Electroporation of Primary Neuronal Cultures In Situ. Electroporation Protocols 145-152 2020.
  13. Li, Linxi, et al. Endogenously produced LG3/4/5-peptide protects testes against toxicant-induced injury. Cell Death & Disease 11 6 44215 2020.
  14. Yang, Xiao-Fei, et al. Direct reprogramming of hepatocytes into insulin-producing cells for anti-diabetic treatment by ultrasound-targeted microbubble destruction enhanced hydrodynamic gene delivery. American Journal of Translational Research 12 11 7275 2020.
  15. Rodriguez, Juan A, et al. Ghrelin receptor agonist rescues excess neonatal mortality in a Prader-Willi syndrome mouse model. Endocrinology 159 12 4006-4022 2018.
  16. Gurramkonda, Chandrasekhar, et al. Improving the recombinant human erythropoietin glycosylation using microsome supplementation in CHO cell‐free system. Biotechnology and Bioengineering 115 51253-1264 2018.
  17. Tran, Kevin, et al. Cell‐free production of a therapeutic protein: Expression, purification, and characterization of recombinant streptokinase using a CHO lysate. Biotechnology and Bioengineering 115 1 92-102 2018.
  18. Hunter, Dominic JB, et al. Unexpected instabilities explain batch‐to‐batch variability in cell‐free protein expression systems. Biotechnology and Bioengineering 11581904-1914 2018.
  19. Peñalber‐Johnstone, Chariz, et al. Optimizing cell‐free protein expression in CHO: Assessing small molecule mass transfer effects in various reactor configurations. Biotechnology and Bioengineering 114 7 1478-1486 2017.
  20. Keating, Sheila M, et al. Generation of recombinant hyperimmune globulins from diverse B-cell repertoires. Nature Biotechnology 44207 2021.
  21. Vazquez-Lombardi, Rodrigo, et al. Transient expression of human antibodies in mammalian cells. Nature Protocols 13 1 99-117 2018.
  22. Nguyen, Annalee W, et al. Engineering Antibodies on the Surface of CHO Cells. Genotype Phenotype Coupling 397-422 2020.
  23. Wang, Chensu, et al. Reprogramming NK Cells and Macrophages via Combined Antibody and Cytokine Therapy Primes Tumors for Elimination by Checkpoint Blockade. CellPress Ahead of Print 2021.
  24. Adler, Adam S, et al. Rare, high-affinity anti-pathogen antibodies from human repertoires, discovered using microfluidics and molecular genomics. MAbs 9 8 1282-1296 2017.
  25. Vazquez-Lombardi, Rodrigo; et al. Expression of IgG Monoclonals with Engineered Immune Effector Functions. Antibody Engineering 313-334 2018.
  26. Piepenbrink, Michael S, et al. Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters. Cell Reports Medicine 2 3 100218 2021.
  27. Haabeth, Ole AW, et al. An mRNA SARS-CoV-2 vaccine employing Charge-Altering Releasable Transporters with a TLR-9 agonist induces neutralizing antibodies and T cell memory. ACS Central Science 2021.
  28. Colluru, Viswa Teja, et al. Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses. Oncoimmunology 5 10 e1223002 2016.
  29. Whitacre, DC, et al. Designing a therapeutic hepatitis B vaccine to circumvent immune tolerance. Human Vaccines & Immunotherapeutics 16 2 251-268 2020.
  30. Kath, Jonas, et al. Fast, efficient and virus-free generation of TRAC-replaced CAR T cells. CellPress Ahead of Print 2021.
  31. Tsuji, Takemasa; et al. Rapid construction of antitumor T-cell receptor vectors from frozen tumors for engineered T-cell therapy. Cancer Immunology Research 6 5 594-604 2018.
  32. Shi, Xiaojing; et al. Genetically engineered cell-derived nanoparticles for targeted breast cancer immunotherapy. Molecular Therapy 28 2 536-547 2020.
  33. Duarte-Sanmiguel, Silvia, et al. Nanoelectroporation and Collection of Genetically Modified Exosomes in Primary Cultures of Dendritic Cells. Electroporation Protocols 79-84 2020.
  34. Cheng, Qinqin, et al. Reprogramming Exosomes for Immunotherapy. Cell Reprogramming for Immunotherapy 197-209 2020.
  35. Koblan, LW, et al., Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. Nature Biotechnology 843-846 2018.
  36. Findlay, GM, et al. Accurate classification of BRCA1 variants with saturation genome editing. Nature 562 217-222 2018.
  37. Hu, JH, et al. Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature 57-63 2018.
  38. Salasova, A, et al. A proteomic analysis of LRRK2 binding partners reveals interactions with multiple signaling components of the WNT/PCP pathway. Molecular Neurodegeneration 12 54 2017.
  39. Jaitin, D.A, et al. Dissecting immune circuits by linking CRISPR-Pooled Screens with Single-Cell RNA-Seq. Cell 1883-1896 2016.
  40. Marshall, R, et al. Rapid and Scalable Characterization of CRISPR Technologies Using an E. coli Cell-Free Transcription-Translation System. Molecular Cell 146-157 2017.
  41. Champer J, et al. Novel CRISPR/Cas9 gene drive constructs reveal insights into mechanisms of resistance allele formation and drive efficiency in genetically diverse populations. PLoS Genetics 13 7 2017.
  42. Aram, R, et al. Tools for Mos1-mediated single copy insertion (mosSCI) with excisable unc-119(+) or NeoR (G418) selection cassettes. microPublication Biology 2019.